ABIVAX Société Anonyme reported earnings results for the half year ended June 30, 2023. For the half year, the company reported sales was EUR 2.3 million compared to EUR 2.3 million a year ago. Net loss was EUR 52 million compared to EUR 21.2 million a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
14.82 EUR | +0.54% | +4.66% | +50.92% |
Apr. 11 | Morgan Stanley Adjusts Price Target on Abivax to $16 From $15, Maintains Equalweight Rating | MT |
Apr. 08 | Transcript : ABIVAX Société Anonyme, 2023 Earnings Call, Apr 08, 2024 |
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+50.92% | 995M | |
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- ABVX Stock
- News Abivax
- ABIVAX Société Anonyme Reports Earnings Results for the Half Year Ended June 30, 2023